leadf
logo-loader
viewBryah Resources Ltd

Bryah Resources granted trading halt with capital raising news pending

The halt will remain until the start of normal trading on Wednesday or when an announcement is released to the market.

ASX sign on building
The company is exploring in Western Australia’s Bryah Basin

Bryah Resources Ltd (ASX:BYH) has a capital raising announcement pending and has been granted a trading halt by the ASX.

The halt will remain in place until the start of normal trading on Wednesday, November 28, 2018, or when the announcement is released to the market, whichever occurs earliest.

Bryah’s shares were 9.8 cents at the close of trade last Friday.

READ: Bryah Resources drills more high-grade gold at Windalah

The company last week received further high-grade gold results from the Windalah prospect within the Bryah Basin project in central Western Australia.

Best result was 5 metres at 6.62 g/t gold from 79 metres including 1-metre at 15.05 g/t.

The results followed assays released in mid-October featuring 27 metres featuring 1.43 g/t from 132 metres.

Follow-up drilling at Windalah will be the main priority for the company in its next phase of copper-gold exploration.

Activities underway or being considered include:

- Geological, geochemical and geophysical interpretation and 3D modelling;
- Heritage surveys and Program of Works approvals; and
- Downhole electromagnetic (DHEM) survey of cased holes at Windalah and Jupiter.

READ: Bryah Resources encounters gold zones up to 27 metres thick at Bryah Basin

Bryah Resources is focused on copper-gold-manganese with two projects in central Western Australia - the 720-square-kilometre Bryah Basin project and the 202-square-kilometre Gabanintha project.

In addition, it holds a one-year option to acquire the historical Horseshoe South Manganese Mine and the manganese mineral rights over a further 154 square kilometres of ground in the basin.

Quick facts: Bryah Resources Ltd

Price: 0.062 AUD

ASX:BYH
Market: ASX
Market Cap: $9.52 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Bionomics' positive pharmacokinetic results confirms it can begin second...

Bionomics Limited (ASX:BNO) (OTCQB:BNOEF) Executive Chairman Errol De Souza tells Proactive tells Proactive the Adelaide, Australia- based biopharmaceutical company has received positive pharmacokinetic results from a 7-day dosing study to treat PTSD, using its new formulation of BNC210. De...

1 day, 8 hours ago

2 min read